Evidence & regulatory context
- Mechanism
- Only the p-hydroxybenzoate component resolved (methylparaben, max_phase -1 i.e. unknown clinical phase; used as an antimicrobial preservative/excipient). ChEMBL holds no mechanism-of-action record for it. Catalase, 1-phenyl-3-pyrazolidone (phenidone) and CGP 35949B returned no confident ChEMBL match. No human trial identified for this combination.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- -1 / 4 (development scale, not regulatory approval)
- Synonyms
- Methyl paraben; Methyl p-hydroxybenzoate; E-218; Tegosept M; Nipagin M; NSC-3827
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatChemical/toxinInbred strain not specifiedMaleAdded to the perfusate of isolated perfused lungsAmphotericin B 1 mg/kg; doses of the protective agents not…
Model: Acute lung injury induced by amphotericin B (1 mg/kg) in intact rats and in isolated lungs perfused with cell-free and plasma-free physiological solution
Amphotericin B produced neutrophil-independent acute lung injury with vasoconstriction and oxidant stress. Methylparaben, catalase, phenidone and CGP 35949B each attenuated the injury in isolated lungs, and methylparaben and CGP 35949B prevented the rise in lung leukotriene C4 and B4.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
